Grants and Contributions:

Title:
513437
Agreement Number:
513437
Agreement Value:
$14,053,500.00
Agreement Date:
Feb 2, 2021 - Dec 31, 2030
Description:
Edesa will complete a pre-clinical study, and Phase II trials to evaluate the safety and efficacy of an antibody treatment (EB05) in hospitalized COVID-19 patients.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:

This investment will allow the company to advance their COVID-19 therapeutic candidate (EB05) through Phase II clinical trials, in hopes of advancing to Phase III. This project anticipates the creation of 6 new full-time jobs and will maintain 8 full-time jobs within Canada.

Location:
Markham, Ontario, CA L3R5+O1+O116
Reference Number:
033-2020-2021-Q4-513437
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
815678123
Recipient Type:
For-profit organization
Additional Information:

Please note this update includes a change to improve standardization of reporting across projects. The end date was updated from the end of the work phase of the project (31/12/2028) to the current end date of the contract (31/12/2030). This is not an extension. The end date now reflects the entirety of the agreement duration, including the benefit phase and residual audit period. The original start date was updated to reflect the correct execution date.

Amendment Date
Mar 31, 2026
Recipient's Operating Name:
Edesa Biotech Research, Inc.
Recipient's Legal Name:
Edesa Biotech Research, Inc.
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
SIF Stream 1 - R&D
Program Purpose:

Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.

NAICS Code:
541710
Amendments: